Treatment with c-Myc inhibitors significantly inhibits PD-L1 transcription, such as in lung cancer, where Bafetinib (a tyrosine kinase inhibitor) can reduce PD-L1 transcription by inhibiting the transcription of c-Myc [209]. This evidence concerns the gene CD274 and lung carcinoma.